You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
先瑞達醫療-B(06669.HK)與BSG訂立諒解備忘錄
格隆匯 06-19 07:12

格隆匯6月19日丨先瑞達醫療-B(06669.HK)發佈公吿,2023年6月15日,公司與Boston Scientific Group plc(“BSG”)訂立諒解備忘錄,據此,Boston Scientific Corporation(“BSC”,連同其附屬公司但不包括集團統稱“BSC集團”)與集團確認雙方有意在多個領域探索合作機會的共識,包括(其中包括)研發、製造以及銷售及營銷。公司及BSC集團擬透過利用各方在科技、技術、經驗及資源方面的優勢,尋求在以下領域進行合作,包括:(a)加強心血管疾病方面的研發,以及為美國、中國、日本及歐洲國家等市場開發產品;開發治療CTO(慢性完全閉塞)病變、下肢動脈狹窄、靜脈曲張、透析患者通路維護及其他領域的產品;(b)以OEM(原設備製造商)基準為另一方製造若干產品,以達致成本效益;(c)在外周、冠狀動脈、腫瘤、泌尿及男科等領域交叉銷售若干產品或推出若干聯乘產品,以最大程度地運用渠道及提升產品價值;及(d)支援另一方進行產品註冊。

於2023年2月完成自願有條件部分要約後,BSG成為公司的控股股東,其後,集團與BSC集團一直探索在研發、製造及商業化方面進行商業合作的機會,以創造協同價值。訂立諒解備忘錄將確認雙方對有關合作的共識。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account